Treatment of severe pemphigus vulgaris with rituximab | [Journal of Pakistan Association of Dermatologists • 2021]

Author(s):

1. Fatima Bashir: Department of Dermatology, Lahore General Hospital,Lahore,Pakistan

2. Aitisam Waheed: Department of Dermatology, Lahore General Hospital,Lahore,Pakistan

3. Madiha Sanai: Department of Dermatology, Lahore General Hospital,Lahore,Pakistan

4. Ahmad Kazmi: Department of Dermatology, Lahore General Hospital,Lahore,Pakistan

5. Aneela Asghar: Department of Dermatology, Lahore General Hospital,Lahore,Pakistan

Abstract:

Pemphigus vulgaris is an autoimmune skin disease mediated by autoantibodies directed against desmoglein-3 and desmoglein-1 located on keratinocytes. Rituximab, a monoclonal anti-CD20 antibody depleting B-cells, offers an effective treatment possibility for therapy-resistant pemphigus vulgaris. Here, we present a case of 20-year-old female who did not respond sufficiently to conventional treatment with prednisolone, azathioprine, mycophenolate mofetil and intravenous immunoglobulins but underwent almost complete remission after rituximab treatment. It was given as two injections of 500mg each at an interval of two weeks in ICU setting.

Page(s): 129-132

DOI: DOI not available

Published: Journal: Journal of Pakistan Association of Dermatologists, Volume: 31, Issue: 1, Year: 2021

Keywords:

Desmoglein , Pemphigus vulgaris PV

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views